Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661129 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL5660852 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL955977 | 0.93 | ALDH1A1 (0.64) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL420011 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL5167895 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL5169003 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL123612 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL1931125 | 0.83 | ALDH1A1 (0.78) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL9770300 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL10917708 | 0.80 | KDM4E (0.53) | ALDH1A1MAPK1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143009-B1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2019-09-18 | — | — | EP | disclosed |
| EP-3143009-B1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2019-09-18 | — | — | EP | disclosed |
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) | 2018-09-06 | — | — | US | disclosed |
| EP-3344257-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | Westfälische Wilhelms-Universität Münster (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| EP-3143009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | Fondazione Istituto Italiano di Tecnologia (IT) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017036880-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | Westfälische Wilhelms-Universität Münster (DE) | 2017-03-09 | — | — | WO | disclosed |
| WO-2015173169-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
| EP-0873990-A1 | BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-10-28 | — | — | EP | disclosed |
| EP-0501693-B1 | Isoquinoline derivatives | BANYU PHARMA CO LTD (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0393574-B1 | Hexitol derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5362736-A | Alkoxy derivatives for cardiovascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-11-08 | — | — | US | disclosed |
| EP-0501693-A1 | Isoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-5140026-A | N-aminoalkyl-S-aryl-S-alkyl (or substituted alkyl) sulfoximines as antiarrhythmic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-08-18 | — | — | US | disclosed |
| US-5053408-A | Cardiovascular disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0393574-A2 | Hexitol derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4724235-A | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-09 | — | — | US | disclosed |
| US-4597902-A | TREATMENT OF CARDIAC ARRHYTHMIAS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | GRIN1, GRIN2B, GRIN3B | ALDH1A1 2771/4885MAPK1 2708/4885HDAC3 696/4885 |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | ALDH1A1 915/4885MAPK1 2752/4885HDAC3 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.